Welcome to the international HTA database

Showing [23378 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	NIHR Health Technology Assessment programme	PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation
2008	National Institute for Health and Care Excellence (NICE)	Promoting children's social and emotional wellbeing in primary education
2003	Israel Center for Technology Assessment in Health Care (ICTAHC)	Promoting Medical Technologies in the national list of health services: 1995-2000
1999	Health Services Utilization and Research Commission (HSURC)	Promoting optimal drug prescribing in Saskatchewan
2015	University of York	Promoting patient-centred care planning consultations
2002	NIHR Health Technology Assessment programme	Promoting physical activity in South Asian Muslim women through 'exercise on prescription'
2000	University of York	Promoting the initiation of breastfeeding
2010	National Institute for Health and Care Excellence (NICE)	Promoting the quality of life of looked-after children and young people
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Prone positioning of patients on extracorporeal membrane oxygenation (ECMO)
2002	Centre for Clinical Effectiveness (CCE)	Prone positioning of patients with acute respiratory distress syndrome (ARDS)
2014	HAYES, Inc.	Pronto-7 with rainbow 4D technology (Masimo Corp.) for noninvasive hemoglobin measurement
2022	National Institute for Health and Care Excellence (NICE)	Prontosan for treating acute and chronic wounds. NICE medical technologies guidance 67
2009	HAYES, Inc.	ProOnc TumorSourceDX miRview mets (Prometheus Laboratories; Rosetta Genomics) microRNA Analysis for Carcinoma of Unknown Primary Origin (CUP)
2017	HAYES, Inc.	Propel and propel mini bioabsorbable steroid-releasing sinus implants for treatment of chronic rhinosinusitis in adults
1994	Health Council of the Netherlands Gezondheidsraad (GR)	Proper use of human tissue
2015	Health Quality Ontario (HQO)	Prophylactic antibiotics for individuals with Chronic Obstructive Pulmonary Disease (COPD): a rapid review
2005	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Prophylactic antibiotics vs prophylactic G-CSF in prevention of febrile neuropenia in patients with a small cell bronchus carcinoma - primary research
2020	Malaysian Health Technology Assessment (MaHTAS)	Prophylactic anticoagulation in ambulatory cancer patients
2000	Centre for Clinical Effectiveness (CCE)	Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events
2000	Centre for Clinical Effectiveness (CCE)	Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events
2015	The Regional Health Technology Assessment Centre (HTA-centrum)	Prophylactic insertion of a gastrostomy for nutritional support in patients with head and neck cancer
2015	NIHR Health Technology Assessment programme	Prophylactic intra-abdominal drains for colorectal surgery
2019	NIHR Health Technology Assessment programme	Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
2002	HAYES, Inc.	Prophylactic mastectomy
2002	HAYES, Inc.	Prophylactic oophorectomy
2013	HAYES, Inc.	Prophylactic oophorectomy for the prevention of ovarian cancer
2019	European Network for Health Technology Assessment (EUnetHTA)	Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)
1998	University of York	Prophylactic removal of impacted third molars: is it justified?
2012	Belgian Health Care Knowledge Centre (KCE)	Prophylactic removal of pathology-free wisdom teeth: rapid assessment
2003	Norwegian Knowledge Centre for the Health Services (NOKC)	Prophylactic removal of wisdom teeth
1996	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Prophylactic sclerotherapy of oesophageal varices - primary research
2001	National Institute for Clinical Excellence (NICE)	Prophylaxis for patients who have experienced a myocardial infarction: drug treatment, cardiac rehabilitation and dietary manipulation - guideline
1992	L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES)	Prophylaxis of infectious endocarditis - consensus conference
2010	HAYES, Inc.	Propofol for moderate sedation during colonoscopy
2005	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Proposal for criteria of public coverage and prioritisation in assisted human reproduction
2002	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Proposal for the indication of PET in oncology with public coverage in Catalonia
2006	Health Council of the Netherlands Gezondheidsraad (GR)	Proposals for research into health effects of electromagnetic fields (0Hz - 300 GHZ)
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Proposed delay for safe surgery after COVID-19
2017	Adelaide Health Technology Assessment (AHTA)	Prosigna (PAM50) for predicting breast cancer recurrence
2014	HAYES, Inc.	Prosigna breast cancer prognostic gene signature assay
2015	HAYES, Inc.	Prosigna Breast Cancer Prognostic Gene Signature Assay
2019	Norwegian Institute of Public Health (NIPH)	Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission
1999	Alberta Heritage Foundation for Medical Research (AHFMR)	Prosorba (R) blood filtration column
2001	Alberta Heritage Foundation for Medical Research (AHFMR)	Prosorba treatment for rheumatoid arthritis
2014	NIHR Health Technology Assessment programme	Prospective multicentre randomised, double-blind, equivalence study comparing clonidine and midazolam as intravenous sedative agents in critically ill children: the SLEEPS (Safety profiLe, Efficacy and Equivalence in Paediatric intensive care Sedation) study
2022	NIHR Health Technology Assessment programme	Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation (LiverTOL-Dx Trial)
2003	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Prospective study into the influence of high-dose chemotherapy with adjuvant treatment with peripheral stem cells on the disease-free survival of patients with mammary carcinoma and four or more metastatic lymph glands in the armpit - primary research
2005	Institute for Clinical Effectiveness and Health Policy (IECS)	Prostacyclins (epoprostenol, iloprost, treprostinil and beraprost) for the management of primary pulmonary hypertension and pulmonary hypertension in collagen vascular disease
2009	Institute for Clinical Effectiveness and Health Policy (IECS)	Prostacyclins (epoprostenol, iloprost, treprostinil and beraprost) for the management of primary pulmonary hypertension and pulmonary hypertension in collagen vascular disease
2007	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prostaglandin analogues for ophthalmic use: analysis of clinical and cost-effectiveness
2001	HAYES, Inc.	Prostascint
2017	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Prostate artery embolisation for benign prostatic hyperplasia
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Prostate artery embolisation for benign prostatic hyperplasia
2018	National Institute for Health and Care Excellence (NICE)	Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 611
2018	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Prostate artery embolisation: poor design and reporting impact the value of current systematic reviews
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia
2006	NIHR Horizon Scanning Centre (NIHR HSC)	Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer: horizon scanning technology briefing
2017	Health Quality Ontario (HQO)	Prostate cancer patient perspectives on the use of information in treatment decision-making: a systematic review and qualitative meta-synthesis
2011	Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS)	Prostate cancer screening
1996	Australian Health Technology Advisory Committee (AHTAC)	Prostate cancer screening (consumer statement)
1996	Australian Health Technology Advisory Committee (AHTAC)	Prostate cancer screening (executive summary)
1996	Australian Health Technology Advisory Committee (AHTAC)	Prostate cancer screening (technical report)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Prostate cancer screening: a review of the guidelines
1999	Basque Office for Health Technology Assessment (OSTEBA)	Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project)
2004	Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA)	Prostate Oncoguide
2010	HAYES, Inc.	Prostate Px (Aureon Laboratories Inc.) for prediction of recurrence of prostate cancer
2006	HAYES, Inc.	Prostate saturation biopsy for diagnosis of prostate cancer
2005	Medical Services Advisory Committee (MSAC)	Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer
1995	Health Services Utilization and Research Commission (HSURC)	Prostate specific antigen (PSA) testing
2003	NIHR Health Technology Assessment programme	Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
1999	NIHR Health Technology Assessment programme	Prostate trials office (PROTO): co-ordinating trials of new technologies in the treatment of BPH
2009	NIHR Health Technology Assessment programme	Prostate trials office (PROTO): co-ordinating trials of new technologies in the treatment of BPH
2002	Institute for Clinical Evaluative Sciences (ICES)	Prostate-specific antigen (PSA) screening in asymptomatic men
2015	Health Quality Ontario (HQO)	Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis
2015	Health Quality Ontario (HQO)	Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis
2002	HAYES, Inc.	Prostate-specific antigen testing for prognosis and monitoring of patients with prostate cancer
2003	HAYES, Inc.	Prostate-specific antigen testing for screening and early detection of prostate cancer
2006	Belgian Health Care Knowledge Centre (KCE)	Prostate-specific-antigen (PSA) for the screening of prostate cancer
2021	Ontario Health	Prostatic artery embolization for benign prostatic hyperplasia
1992	Danish Institute for Health Services Research (DSI)	Prostatic cancer in the Nordic Countries
2022	National Institute for Health and Care Excellence (NICE)	Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 737
2008	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Prostheses for primary total hip replacement in Italy
2009	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Prostheses for primary total knee replacement in Italy
2012	The Regional Health Technology Assessment Centre (HTA-centrum)	Prosthetic arthroplasty in primary shoulder osteoarthritis
1994	University HealthSystem Consortium (UHC)	Prosthetic hip and knee arthroplasty
2004	National Institute for Clinical Excellence (NICE)	Prosthetic intervertebral disc replacement
2006	Institute for Clinical Effectiveness and Health Policy (IECS)	Prosthetic intervertebral disc replacement
2005	National Institute for Clinical Excellence (NICE)	Prosthetic intervertebral disc replacement in the cervical spine
2010	National Institute for Health and Care Excellence (NICE)	Prosthetic intervertebral disc replacement in the cervical spine
2010	National Institute for Health and Care Excellence (NICE)	Prosthetic intervertebral disc replacement in the cervical spine. NICE interventional procedures guidance 341
2009	National Institute for Health and Care Excellence (NICE)	Prosthetic intervertebral disc replacement in the lumbar spine. NICE interventional procedures guidance 306
2010	The Swedish Council on Health Technology Assessment (SBU)	Prosthetic rehabilitation of partially dentate or edentulous patients
2013	NIHR Horizon Scanning Centre (NIHR HSC)	PROSTVAC Immunotherapy for chemotherapy-naïve hormone-relapsed prostate cancer
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Protease inhibitor use for chronic hepatitis C infection in prior null responders and recurrent hepatitis C infection post liver transplant: a review of the clinical evidence
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Protease inhibitor use for chronic hepatitis C infection in special populations: a review of the clinical evidence and guidelines
1996	Health Council of the Netherlands Gezondheidsraad (GR)	Protection against diphtheria
1996	Health Council of the Netherlands Gezondheidsraad (GR)	Protection against Hepatitis B
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Protein testing in patients with multiple myeloma: a review of clinical effectiveness and guidelines
2008	HAYES, Inc.	Prothrombin G20210A for risk assessment for venous thromboembolism (VTE) or obstetric complications
2024	Health Information and Quality Authority (HIQA)	Protocol for a health technology assessment of screening for abdominal aortic aneurysm in men